[Skip to Content]
[Skip to Content Landing]

Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees

Educational Objective
To examine the association of state implementation of medical and adult-use marijuana laws with opioid prescribing rates and spending among Medicaid enrollees.
1 Credit CME
Key Points

Question  Are medical and adult-use marijuana laws passed after 2010 associated with lower rates of opioid prescribing for Medicaid enrollees?

Findings  In this population-based, cross-sectional study using the all-capture Medicaid prescription data for 2011 to 2016, medical marijuana laws and adult-use marijuana laws were associated with lower opioid prescribing rates (5.88% and 6.38% lower, respectively).

Meaning  Medical and adult-use marijuana laws have the potential to lower opioid prescribing for Medicaid enrollees, a high-risk population for chronic pain, opioid use disorder, and opioid overdose, and marijuana liberalization may serve as a component of a comprehensive package to tackle the opioid epidemic.

Abstract

Importance  Overprescribing of opioids is considered a major driving force behind the opioid epidemic in the United States. Marijuana is one of the potential nonopioid alternatives that can relieve pain at a relatively lower risk of addiction and virtually no risk of overdose. Marijuana liberalization, including medical and adult-use marijuana laws, has made marijuana available to more Americans.

Objective  To examine the association of state implementation of medical and adult-use marijuana laws with opioid prescribing rates and spending among Medicaid enrollees.

Design, Setting, and Participants  This cross-sectional study used a quasi-experimental difference-in-differences design comparing opioid prescribing trends between states that started to implement medical and adult-use marijuana laws between 2011 and 2016 and the remaining states. This population-based study across the United States included all Medicaid fee-for-service and managed care enrollees, a high-risk population for chronic pain, opioid use disorder, and opioid overdose.

Exposures  State implementation of medical and adult-use marijuana laws from 2011 to 2016.

Main Outcomes and Measures  Opioid prescribing rate, measured as the number of opioid prescriptions covered by Medicaid on a quarterly, per-1000-Medicaid-enrollee basis.

Results  State implementation of medical marijuana laws was associated with a 5.88% lower rate of opioid prescribing (95% CI, −11.55% to approximately −0.21%). Moreover, the implementation of adult-use marijuana laws, which all occurred in states with existing medical marijuana laws, was associated with a 6.38% lower rate of opioid prescribing (95% CI, −12.20% to approximately −0.56%).

Conclusions and Relevance  The potential of marijuana liberalization to reduce the use and consequences of prescription opioids among Medicaid enrollees deserves consideration during the policy discussions about marijuana reform and the opioid epidemic.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: February 16, 2018.

Corresponding Author: Hefei Wen, PhD, Department of Health Management & Policy, University of Kentucky College of Public Health, Lexington, KY 40536 (hefei.wen@uky.edu).

Published Online: April 2, 2018. doi:10.1001/jamainternmed.2018.1007

Author Contributions: Both authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Both authors.

Acquisition, analysis, or interpretation of data: Both authors.

Drafting of the manuscript: Both authors.

Critical revision of the manuscript for important intellectual content: Both authors.

Statistical analysis: Wen.

Conflict of Interest Disclosures: None reported.

References
1.
Bohnert  AS, Valenstein  M, Bair  MJ,  et al.  Association between opioid prescribing patterns and opioid overdose-related deaths.  JAMA. 2011;305(13):1315-1321.PubMedGoogle ScholarCrossref
2.
Volkow  ND. America’s addiction to opioids: heroin and prescription drug abuse. Washington, DC: Senate Caucus on International Narcotics Control. May 14, 2014. https://www.drugcaucus.senate.gov/sites/default/files/Volkow%20Testimony.pdf. Accessed July 12, 2017.
3.
Dowell  D, Zhang  K, Noonan  RK, Hockenberry  JM.  Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates.  Health Aff (Millwood). 2016;35(10):1876-1883.PubMedGoogle ScholarCrossref
4.
Cicero  TJ, Ellis  MS, Surratt  HL, Kurtz  SP.  The changing face of heroin use in the United States: a retrospective analysis of the past 50 years.  JAMA Psychiatry. 2014;71(7):821-826.PubMedGoogle ScholarCrossref
5.
Bachhuber  MA, Saloner  B, Cunningham  CO, Barry  CL.  Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.  JAMA Intern Med. 2014;174(10):1668-1673.PubMedGoogle ScholarCrossref
6.
Wilkinson  ST, Yarnell  S, Radhakrishnan  R, Ball  SA, D’Souza  DC.  Marijuana legalization: impact on physicians and public health.  Annu Rev Med. 2016;67:453-466.PubMedGoogle ScholarCrossref
7.
Lynch  ME, Campbell  F.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.  Br J Clin Pharmacol. 2011;72(5):735-744.PubMedGoogle ScholarCrossref
8.
Hill  KP.  Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review.  JAMA. 2015;313(24):2474-2483.PubMedGoogle ScholarCrossref
9.
National Academies of Sciences, Engineering, and Medicine.  The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
10.
National Conference of State Legislation (NCSL). Deep Dive: Marijuana. Denver, CO: National Conference of State Legislation. 2016. http://www.ncsl.org/bookstore/state-legislatures-magazine/marijuana-deep-dive.aspx. Accessed July 12, 2017.
11.
Lynskey  MT, Heath  AC, Bucholz  KK,  et al.  Escalation of drug use in early-onset cannabis users vs co-twin controls.  JAMA. 2003;289(4):427-433.PubMedGoogle ScholarCrossref
12.
Hathaway  AD, Comeau  NC, Erickson  PG.  Cannabis normalization and stigma: contemporary practices of moral regulation.  Criminol Crim Justice. 2011;11(5):451-469. doi.org/10.1177/1748895811415345Google ScholarCrossref
13.
Shi  Y.  Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever.  Drug Alcohol Depend. 2017;173:144-150.PubMedGoogle ScholarCrossref
14.
Kim  JH, Santaella-Tenorio  J, Mauro  C,  et al.  State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers.  Am J Public Health. 2016;106(11):2032-2037.PubMedGoogle ScholarCrossref
15.
Bradford  AC, Bradford  WD.  Medical marijuana laws reduce prescription medication use in Medicare part D.  Health Aff (Millwood). 2016;35(7):1230-1236.PubMedGoogle ScholarCrossref
16.
Bradford  AC, Bradford  WD.  Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees.  Health Aff (Millwood). 2017;36(5):945-951.PubMedGoogle ScholarCrossref
17.
Livingston  MD, Barnett  TE, Delcher  C, Wagenaar  AC.  Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015.  Am J Public Health. 2017;107(11):1827-1829.PubMedGoogle ScholarCrossref
18.
Castlight Health. The opioid crisis in America’s workforce. San Francisco, CA: Castlight Health Inc; 2016. http://content.castlighthealth.com/Opioid-Research-Report_LP.html. Accessed July 12, 2017.
19.
Center for Medicaid and CHIP Services. Medicaid drug programs data and resources. Baltimore, MD: Centers for Medicare and Medicaid Services (CMS); 2017. http://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/medicaid-drug-programs-data-and-resources.html. Accessed July 12, 2017.
20.
Han  B, Compton  WM, Jones  CM, Cai  R.  Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013.  JAMA. 2015;314(14):1468-1478.PubMedGoogle ScholarCrossref
21.
Cicero  TJ, Ellis  MS.  Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin.  JAMA Psychiatry. 2015;72(5):424-430.PubMedGoogle ScholarCrossref
22.
Chou  R, Fanciullo  GJ, Fine  PG,  et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.  J Pain. 2009;10(2):113-130.PubMedGoogle ScholarCrossref
23.
US Department of Veterans Affairs. VA/DoD clinical practice guidelines: management of opioid therapy (OT) for chronic pain. Washington, DC: US Department of Veterans Affairs (VA); 2010. https://www.healthquality.va.gov/guidelines/Pain/cot/. July 12, 2017.
24.
Murthy  VH. Letter From the Surgeon General. Washington, DC: Office of the Surgeon General, U.S. Department of Health and Human Services (HHS); August 25, 2016. https://turnthetiderx.org/. Accessed July 12, 2017.
25.
Dowell  D, Haegerich  TM, Chou  R.  CDC guideline for prescribing opioids for chronic pain—United States, 2016.  JAMA. 2016;315(15):1624-1645.PubMedGoogle ScholarCrossref
26.
Kuehn  BM; FDA committee.  FDA committee: more restrictions needed on hydrocodone combination products.  JAMA. 2013;309(9):862.PubMedGoogle ScholarCrossref
27.
Pacula  RL, Powell  D, Heaton  P, Sevigny  EL.  Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details.  J Policy Anal Manage. 2015;34(1):7-31.PubMedGoogle ScholarCrossref
28.
Wooldridge  JM.  Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press; 2010.
29.
Volkow  ND, McLellan  AT.  Opioid abuse in chronic pain—misconceptions and mitigation strategies.  N Engl J Med. 2016;374(13):1253-1263.PubMedGoogle ScholarCrossref
30.
Marist College Institute for Public Opinion. Yahoo News/Marist Poll Weed & the American family. Poughkeepsie, NY: Marist College Institute for Public Opinion; 2017. http://maristpoll.marist.edu/yahoo-newsmarist-poll/. Accessed February 7, 2018.
31.
Ren  Y, Whittard  J, Higuera-Matas  A, Morris  CV, Hurd  YL.  Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.  J Neurosci. 2009;29(47):14764-14769.PubMedGoogle ScholarCrossref
32.
McCarthy  J. Record-high support for legalizing marijuana use in U.S. Washington, DC: Gallup News; 2017. http://news.gallup.com/poll/221018/record-high-support-legalizing-marijuana.aspx. Accessed November 29, 2017.
33.
Kolodny  A, Courtwright  DT, Hwang  CS,  et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.  Annu Rev Public Health. 2015;36:559-574.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements